CB Therapeutics is a Carlsbad, California-based synthetic biology company developing biosynthetic psychedelic compounds and their novel analogues using a proprietary yeast fermentation platform. Founded in 2015, the company has raised $11.62M from investors including Y Combinator, Pioneer Fund, and re.Mind Capital. CB Therapeutics has achieved biosynthesis of psilocybin, psilocin, DMT, and MDMA analogs, holds seven granted patents with twelve pending, and has partnered with atai Life Sciences and Cleveland Clinic for clinical supply. Its PsyVault™ platform houses the largest collection of biosynthetic psychedelics and analogues.
Drug Pipeline
2Biosynthetic psilocybin / psilocin
PsilocybinBiosynthetic psilocybin and psilocin produced via proprietary yeast fermentation; Cleveland Clinic collaboration for clinical supply.
DMT and tryptamine analogues
DMTFirst successful yeast-based biosynthesis of DMT and related analogues; atai Life Sciences partnership.
Quick Facts
- Type
- Private Biotech
- Founded
- 2015
- Lead Stage
- Discovery
- Website
- Visit